Long-Term Graft Survival with or without Donor-Specific Transfusion in Cyclosporine Era in One Haplo-Identical Living-Related Renal Transplant Recipients beyond the First Year: A 19-Year Experience.

2002 ◽  
Vol 197 (4) ◽  
pp. 201-207 ◽  
Author(s):  
SHIGERU SATOH ◽  
JUN SUGIMURA ◽  
SO OMORI ◽  
KOJI SEINO ◽  
ISAO FUJIZUKA
Keyword(s):  
Renal Transplant ◽  
Graft Survival ◽  
First Year ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Living Related

Nutritional Status in Japanese Renal Transplant Recipients With Long-term Graft Survival

2015 ◽  
Vol 47 (2) ◽  
pp. 367-372 ◽  
Author(s):  
H. Sasaki ◽  
A. Suzuki ◽  
M. Kusaka ◽  
N. Fukami ◽  
R. Shiroki ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Nutritional Status ◽  
Graft Survival ◽  
Renal Transplant Recipients ◽  
Transplant Recipients

scholarly journals Effect of Mycophenolate Mofetil on Long-Term Outcomes in African American Renal Transplant Recipients

2000 ◽  
Vol 11 (12) ◽  
pp. 2366-2370
Author(s):  
HERWIG-ULF MEIER-KRIESCHE ◽  
AKINLOLU O. OJO ◽  
ALAN B. LEICHTMAN ◽  
JEFFREY D. PUNCH ◽  
JULIE A. HANSON ◽  
...  
Keyword(s):  
African American ◽  
African Americans ◽  
Renal Transplant ◽  
Graft Survival ◽  
Patient Survival ◽  
The United States ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Data Registry

Abstract. African American renal transplant recipients have poorer graft survival. A study using the United States Renal Data Registry documented an improvement in graft survival for patients who took mycophenolate mofetil (MMF) compared with azathioprine (AZA). This analysis did not address the impact of MMF on African American renal transplant recipients. The present study aimed to quantify potential beneficial effects of MMF therapy on long-term renal allograft survival in African Americans. With the use of the United States Renal Data Registry, all adult Caucasian and African American patients who had received a primary renal transplant between 1988 and 1997 were analyzed by Kaplan-Meier analysis and Cox proportional hazard models. Primary study end points were death with a functioning graft and graft failure censored for death. A total of 57,926 patients were studied. For African Americans, 3-yr patient survival was 96.3 versus 93.2% (P < 0.001) for MMF and AZA, respectively. Three-yr death-censored graft survival for African Americans was 85.8 versus 75.1% (P < 0.001) for MMF and AZA, respectively. For Caucasians, 3-yr patient survival was 97.3 versus 93.2% for MMF and AZA, respectively. Three-yr death-censored graft survival for Caucasians was 90.1 versus 86.4% (P < 0.001) for MMF and AZA, respectively. By multivariate analysis, MMF was associated with a significant reduction in the relative risk for all study end points in African Americans. MMF therapy is associated with both improved patient and death-censored graft survival in African American renal transplant recipients. This benefit is comparable to the benefit of MMF in Caucasian renal transplant recipients.

scholarly journals Improvement in long-term graft survival in cadaveric renal transplant recipients treated with mycophenolate mofetil

2004 ◽  
Vol 17 (9) ◽  
pp. 525-530
Author(s):  
Marc Hazzan ◽  
Francois Provot ◽  
Francois Glowacki ◽  
Marie Christine Copin ◽  
Didier Roumilhac ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplant ◽  
Graft Survival ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Cadaveric Renal Transplant
Sign in / Sign up

Export Citation Format

Share Document